CD45RC

CD45RCNCBI

CD45RC

PHA stimulated rat lymphocytes.

This product recognises rat CD45RC the high molecular weight form of the leucocyte common antigen. The antigen is found on B cells approximately 50% of bone marrow cells all CD8+ve T cells but splits CD4+ve T cells into two populations CD4+CD45RChigh (Th1-like) and CD4+CD45RClow (Th2-like). This product is routinely tested in flow cytometry on rat splenocytes.

Phosphate buffered saline pH7. 2

Use 10ul of the suggested working dilution to label 106 cells in 100ul. Suggested

Required for T-cell activation through the antigen receptor. The first PTPase domain has enzymatic activity while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation recruits an dephosphorylates SKAP1 and FYN.

Binds GANAB and PRKCSH (By similarity). Interacts with SKAP1.

The first PTPase domain interacts with SKAP1.

Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+)SCID) [MIM:608971]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity leukopenia and low or absent antibody levels. Patients with SCID present in infancy with recurrent persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.

Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.

Contains 2 tyrosine-protein phosphatase domains. 1. Spickett. G. P. et al. (1983) MRC OX-22. a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen. 2. Arthur. R. P. and Mason. D. W. (1986) T cells that help B cell responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. 3. Pelegri. C et al. (2001) Prevention of adjuvant arthritis by the W3/25 anti-CD4 monoclonal antibody is associated with a decrease of blood CD4+CD45RChigh T cells.